Pharmacists: Bispecifics and Operational Role

Robert Mancini, PharmD, reviews pharmacists’ pivotal role in operationalizing use of bispecifics in diffuse large B-cell lymphoma (DLBCL), overcoming challenges, and supporting direct patient care teams.

Related Keywords

Robert Mancini ,Zahra Mahmoudjafari ,Aamir Ali , ,Practice Pearls ,Bispecific Antibodies ,Dlbcl ,Clinical Trials ,Epcorinomab ,Glofitomab ,Approval ,Response Rates ,Duration Of Response ,Progression Free Survival ,Toxicity Profiles ,Crs ,Neurotoxicity ,Trial Design ,Patient Cohorts ,Biospecific Treatments ,Lymphoma Therapy ,Step Up Dosing ,Outpatient Administration ,Patient Education ,Side Effect Management ,Treatment Pathways ,Institutional Preferences ,Decision Making Processes ,Immunotherapy Options ,Side Effect Correlation ,Reatment Adaptation ,Response Assessment ,Tumor Flare Monitoring ,